NHS

R&D

Early detection of cancers will require blood sweat and tear...

An NHS study of a new cancer blood test holds huge promise, but will not be without its challenges, says Snedden Campbell’s Ivor Campbell.

News

Keytruda backed by NICE for late-stage oesophageal cancer

MSD's Keytruda has become the first immunotherapy cleared by NICE for previously-untreated patients with advanced oesophageal cancer, making it an option for routine NHS treatment.

Patients

Taking stock of NHS medicines optimisation

Given the rising cost of medicines as a share of the NHS budget in England, the establishment of ICSs provides a timely opportunity to take stock on delivering medicines optimisation at loc

News

NHS England starts largest ever trial of Galleri cancer bloo...

A blood test called Galleri that could detect dozens of different forms of cancer before symptoms appear will start trials by the NHS in England involving around 140,000 subjects.<

News

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

Amgen's first-in-class KRAS inhibitor Lumykras has been approved in Great Britain and arrives already armed with an agreement to allow early access while its cost-effectiveness is appraised

News

NICE changes its mind on J&J's Erleada in prostate cancer

NICE has reversed its position on Johnson & Johnson's oral prostate cancer therapy Erleada in patients with hormone-relapsed or hormone sensitive tumours, backing NHS use of the drug.

Early detection of cancers will require blood sweat and tear...

Keytruda backed by NICE for late-stage oesophageal cancer

Taking stock of NHS medicines optimisation

NHS England starts largest ever trial of Galleri cancer bloo...

NHS fast tracks access to Amgen's just-approved KRAS cancer ...

NICE changes its mind on J&J's Erleada in prostate cancer

Australia starts probe into AI infiltration of Medicare

Discover a new era of healthcare panel engagement: Grounded ...

NHS

Editor's Picks